Thymoglobulin prophylaxis for prevention of chronic graft-versus-host disease after unrelated or mismatched related peripheral blood stem cell transplantation

Phase 2, open-label trial of antithymocyte globulin in chronic graft-versus-host disease (cGVHD) (3 arms), sponsored by Royal Melbourne Hospital. Primary endpoints: Incidence of extensive chronic graft-versus-host disease versus historical controls and Relationship between rabbit IgG levels and graft-versus-host disease outcome. Started Apr 2009; status: recruiting.